18889881171
Kalkine 0
countryflagUS

Bio Path Holdings Inc

Healthcare US BPTH

0.1899USD
0.0049(2.65%)

Last update at 2025-05-19T18:07:00Z

Day Range

0.190.19
LowHigh

52 Week Range

0.5912.00
LowHigh

Fundamentals

  • Previous Close 0.18
  • Market Cap3.19M
  • Volume739
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.97600M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-8.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -13.86800M -10.44000M -10.88200M -8.59900M -8.58300M
Minority interest - - - - -
Net income -13.83500M -10.43700M -10.85600M -8.50500M -8.58300M
Selling general administrative 4.74M 4.53M 4.33M 4.11M 3.38M
Selling and marketing expenses - - - - -
Gross profit - - - - 0.00000M
Reconciled depreciation 0.18M 0.16M 0.15M 0.23M 0.43M
Ebit -13.90100M -10.44300M -10.90800M -8.69300M -7.37400M
Ebitda -13.72300M -10.28200M -10.75700M -8.46300M -6.94800M
Depreciation and amortization 0.18M 0.16M 0.15M 0.23M 0.43M
Non operating income net other - - 0.03M 0.09M 0.00700M
Operating income -13.90100M -10.44300M -10.90800M -8.69300M -8.59000M
Other operating expenses 13.90M 10.44M 10.91M 8.69M 7.98M
Interest expense -0.03300M 0.00300M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 0.03M 0.00300M 0.03M 0.09M 0.00700M
Net interest income 0.03M 0.00300M 0.03M 0.09M 0.00700M
Extraordinary items - - - - -
Non recurring - - - - 0.61M
Other items - - - - -
Income tax expense -0.03300M -0.00300M -0.02600M -0.09400M -0.60800M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 13.90M 10.44M 10.91M 8.69M 7.98M
Cost of revenue - - - - 0.00000M
Total other income expense net 0.03M 0.00300M 0.03M 0.09M -0.60800M
Discontinued operations - - - - -
Net income from continuing ops -13.86800M -10.44000M -10.88200M -8.59900M -8.58300M
Net income applicable to common shares - -10.44000M -10.88200M -8.59900M -8.58300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 3.22M 15.97M 26.57M 16.48M 22.66M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.99M 5.23M 2.37M 2.20M 0.79M
Total liab 2.78M 1.80M 1.11M 1.41M 1.57M
Total stockholder equity 0.44M 14.17M 25.46M 15.07M 21.09M
Deferred long term liab - - - - -
Other current liab 1.35M 0.91M 0.77M 0.97M 0.67M
Common stock 0.00100M 0.00800M 0.00700M 0.00500M 0.00400M
Capital stock 0.00100M 0.00800M 0.00700M 0.00500M 0.00400M
Retained earnings -107.60700M -91.52900M -77.66100M -67.22100M -56.33900M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M - - 0.52M -
Cash 1.05M 10.38M 23.77M 13.76M 20.43M
Cash and equivalents - - - - -
Total current liabilities 1.91M 1.68M 0.96M 1.17M 1.24M
Current deferred revenue - - - - -
Net debt -0.93900M -10.16300M -23.53900M -13.42500M -20.01100M
Short term debt 0.10M 0.11M 0.08M 0.09M 0.09M
Short long term debt - - - - -
Short long term debt total 0.11M 0.22M 0.23M 0.33M 0.41M
Other stockholder equity 108.05M 105.69M 103.11M 82.29M 77.42M
Property plant equipment - - 0.43M 0.23M 0.30M
Total current assets 3.04M 15.62M 26.14M 15.96M 21.99M
Long term investments - - - - -
Net tangible assets - - 25.46M 15.07M 21.09M
Short term investments - - - - -
Net receivables 0.00000M - - - -
Long term debt - - - - -
Inventory 0.00063M - 0.52M 1.27M 0.78M
Accounts payable 0.46M 0.67M 0.11M 0.10M 0.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -0.72600M
Additional paid in capital - - - - -
Common stock total equity - - - 0.00500M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -67.22100M -56.33900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 0.16M 0.23M 0.29M -13.40500M
Deferred long term asset charges - - - - -
Non current assets total 0.18M 0.36M 0.43M 0.52M 0.67M
Capital lease obligations 0.11M 0.22M 0.23M 0.33M 0.41M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.02100M -0.07000M - 0.00000M -0.01700M
Change to liabilities - -0.19900M -0.08400M -0.16800M 0.33M
Total cashflows from investing activities - -0.07000M -0.07000M -0.07000M -0.01700M
Net borrowings - - - - -
Total cash from financing activities 1.73M 20.01M 4.29M 27.78M 1.18M
Change to operating activities - -0.26000M -0.72200M -0.50800M 0.34M
Net income -13.86800M -10.44000M -10.88200M -8.59900M -8.58300M
Change in cash -13.39000M 10.02M -6.67100M 19.42M -4.96100M
Begin period cash flow 23.77M 13.76M 20.43M 1.00M 5.96M
End period cash flow 10.38M 23.77M 13.76M 20.43M 1.00M
Total cash from operating activities -15.10300M -9.91700M -10.96000M -8.36100M -6.12400M
Issuance of capital stock 1.73M 15.85M 4.29M 26.70M 1.18M
Depreciation 0.18M 0.16M 0.15M 0.23M 0.43M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - 4.29M 27.78M 1.18M
Other cashflows from financing activities -0.02100M 4.16M - 1.08M -0.01700M
Change to netincome - 0.82M 0.58M 0.68M 1.16M
Capital expenditures 0.02M 0.07M 0.07M 0.07M 0.02M
Change receivables - - - - -
Cash flows other operating - - -0.64300M -0.41200M 0.55M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - -6.67100M 19.42M -4.96100M
Change in working capital -2.26400M -0.45900M -0.80600M -0.67600M 0.87M
Stock based compensation 0.85M 0.82M 0.58M 0.68M 0.55M
Other non cash items - 10.90M 5.15M -20.61000M 0.61M
Free cash flow -15.12400M -9.98700M -10.96000M -8.36100M -6.14100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BPTH
Bio Path Holdings Inc		 0.0049 2.65% 0.19 - - - 2.33 0.03
NVO
Novo Nordisk A/S		 2.24 3.48% 66.61 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.26 5.15% 66.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.07 0.02% 438.72 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -0.11 0.02% 594.21 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Bio Path Holdings Inc

4710 Bellaire Boulevard, Bellaire, TX, United States, 77401

Key Executives

Name Title Year Born
Mr. Peter H. Nielsen MBA Co-Founder, Chairman, CEO, Pres, CFO & Treasurer 1949
Mr. Douglas P. Morris Co-Founder, Director of Investor Relations, Sec. & Director 1956
Mr. Anthony Price Sr. VP of Fin., Accounting & Admin. NA
Dr. Ana Tari Ashizawa Ph.D., MBA Sr. VP of Research, Devel. & Clinical Design NA
Dr. Alan MacKenzie Ph.D. Consultant NA
Dr. Thomas A. Walker Ph.D. Consultant NA
Dr. Jeffery Lancet M.D. Consultant NA
Ms. Victoria Lake Rac Regulatory Consultant NA
Mr. Peter H. Nielsen MBA Co-Founder, Chairman of the Board, CEO, President, CFO & Treasurer 1949
Mr. Douglas P. Morris Co-Founder, Director of Investor Relations, Secretary & Director 1956

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.